Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.39 |
| ▸ | PDE4A | P27815 | 6/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | HGF | P14210 | 2/20 | 0.37 |
| ▸ | MST1R | Q04912 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584400 | 0.92 | MAPK1 (0.41) | CNR2TP53MDM2PDE4BPDE4A | |
| SCHEMBL1924566 | 0.91 | ALDH1A1 (0.42) | CNR2TP53MDM2PDE4BPDE4A | |
| Hydrochloric Acid SCHEMBL1926679 | 0.90 | ALDH1A1 (0.41) | CNR2TP53MDM2PDE4BPDE4A | |
| SCHEMBL1925787 | 0.88 | PDE4A (0.44) | TP53MDM2PDE4BPDE4APDE4C | |
| SCHEMBL1924860 | 0.86 | GRIN1 (0.42) | PDE4BPDE4APDE4CPDE4DMAPK1 | |
| Hydrochloric Acid SCHEMBL1926227 | 0.85 | GRIN1 (0.41) | PDE4BPDE4APDE4CPDE4DMAPK1 | |
| SCHEMBL5584383 | 0.84 | CNR2 (0.39) | CNR2TP53MDM2KDM1A | |
| SCHEMBL5584164 | 0.84 | TP53 (0.46) | CNR2TP53MDM2PDE4BPDE4A | |
| SCHEMBL1924631 | 0.83 | ALDH1A1 (0.44) | CNR2TP53MDM2PDE4BPDE4A | |
| SCHEMBL5584157 | 0.80 | TP53 (0.41) | CNR2TP53MDM2PDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | KOWA CO., LTD. (JP) | 2006-06-29 | — | — | US | claimed |
| EP-1604984-A1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVE AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2005-12-14 | — | — | EP | claimed |
| US-6861428-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-03-01 | — | — | US | claimed |
| US-7211577-B2 | Water-soluble phenylpyridazine derivative and medicine containing the same | KOWA CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | KOWA CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| EP-1604984-A1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVE AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-6861428-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | IL1B, IL1A, IL1R1 | CNR2 2914/4885TP53 1443/4885MDM2 2048/4885 |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | CNR2 1362/4885TP53 1226/4885MDM2 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.